Protocol Ledger

NCT05292196 · Phase II · TERMINATED

A Phase II Clinical Trial of TQC3721 Suspension for Inhalation

Interventional Phase II clinical trial protocol NCT05292196 sponsored by Chia Tai Tianqing Pharmaceutical Group Co in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-05-20 Enrollment: 59 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05292196
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)59 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05292196
Protocol FieldVerified Registry Value
NCT IdentifierNCT05292196
Consolidated Lead SponsorChia Tai Tianqing Pharmaceutical Group Co
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment59 participants (ACTUAL)
Registered Start Date2022-05-20
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI